Published in

Springer Sciences + Business Media, Current Molecular Biology Reports, 1(7), p. 1-7, 2021

DOI: 10.1007/s40610-020-00142-z

Links

Tools

Export citation

Search in Google Scholar

alpha-2-Macroglobulin, a Native and Powerful Proteinase Inhibitor, Prevents Cartilage Degeneration Disease by Inhibiting Majority of Catabolic Enzymes and Cytokines

Journal article published in 2021 by Mengbo Zhu ORCID, Bin Zhao, Lei Wei, Shaowei Wang
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown
Data provided by SHERPA/RoMEO

Abstract

Abstract Purpose of Review This review aims at outlining alpha-2-macroglobulin (A2M) injection, a novel non-operation strategy which could delay the process of osteoarthritis (OA). Meanwhile, some burning issues concerning “experimental” and “applied” are also indicated in this review. Recent Findings Many researchers have found that the alpha-2-macroglobulin, a sort of broad-spectrum proteinase inhibitor, presents remarkable inhibitive effect on intra-articular inflammation. Additionally, results of animal experiments prove that the A2M can postpone cartilage degeneration. Some treatments, such as hyaluronic acid (HA), which have been applied clinically for many years proved not to be as effective; thus, the advantage of A2M is presented. Summary A2M promises to be a new strategy of non-operative treatment of OA for its excellent anti-inflammation effect and biosafety. Better improved pharmaceutical preparations and treatment strategies shall be developed with the in-depth research.